« Previous
Next »
The American Journal of Surgery
Volume 194, Issue 5
, Pages 594-599
, November 2007
Expression patterns of lymphangiogenic and angiogenic factors in a model of breast ductal carcinoma in situ
References
- . Sentinel lymph node biopsy for DCIS: Are we approaching consensus?. Ann Surg Oncol. 2007;14:2178–2181
- Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ. J Exp Clin Cancer Res. 2006;25:223–227
- Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516–526
- Role of sentinel lymph node biopsy inductal carcinoma-in-situ treated by mastectomy. Ann Surg Oncol. 2006;14:638–645
- Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts. Int J Cancer. 2007;120:2127–2134
- Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst. 1993;85:1725–1732
- . Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med. 2005;143:446–457
- . Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96:906–920
- . Targeting lymphangiogenesis to prevent tumor metastasis. Br J Cancer. 2006;94:1355–1360
- Julian T, Fourchotte V, Anderson S, et al. Predictive factors that identify patients not requiring a sentinel node biopsy: continued analysis of the NSABP B-32 sentinel node trial. Poster presented at: San Antonio Breast Cancer Symposium; December 14–17, 2006; San Antonio, TX.
- Flt-4-positive vessel density correlates with vascular endothelial growth factor-D expression, nodal status, and prognosis in breast cancer. Clin Cancer Res. 2003;9:5313–5317
- Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer. 2005;92:1720–1728
- An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res. 2007;9:R8;(doi;10.1186/bcr1641)
- . MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst. 2000;92:1185–1186
- . Xenograft models of premalignant breast disease. J Mam Gland Biol Neoplasia. 2000;5:379–391
- Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276:1423–1425
- VEGF-D promotes the metastatic spread oftumor cells via the lymphatics. Nat Med. 2001;7:186–191
- Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92:3566–3570
- VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999;154:1381–1390
- Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes. Int J Cancer. 2005;115:388–392
- LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144:789–801
- Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192–198
- LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res. 2001;61:8079–8084
- Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells. Invest Ophthalmol Vis Sci. 2005;46:4536–4540
- . Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol. 2000;12:581–586
PII: S0002-9610(07)00638-1
doi: 10.1016/j.amjsurg.2007.08.007
© 2007 Excerpta Medica Inc. All rights reserved.
« Previous
Next »
The American Journal of Surgery
Volume 194, Issue 5
, Pages 594-599
, November 2007
